Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
Oncotarget ; 7(34): 55302-55312, 2016 Aug 23.
Article En | MEDLINE | ID: mdl-27486814

Nucleophosmin (NPM1) is a ubiquitous multifunctional phosphoprotein with both oncogenic and tumor suppressor functions. Mutations of the NPM1 gene are the most frequent genetic alterations in acute myeloid leukemia (AML) and result in the expression of a mutant protein with aberrant cytoplasmic localization, NPMc+. Although NPMc+ causes myeloproliferation and AML in animal models, its mechanism of action remains largely unknown. Here we report that NPMc+ activates canonical Wnt signaling during the early phases of zebrafish development and determines a Wnt-dependent increase in the number of progenitor cells during primitive hematopoiesis. Coherently, the canonical Wnt pathway is active in AML blasts bearing NPMc+ and depletion of the mutant protein in the patient derived OCI-AML3 cell line leads to a decrease in the levels of active ß-catenin and of Wnt target genes. Our results reveal a novel function of NPMc+ and provide insight into the molecular pathogenesis of AML bearing NPM1 mutations.


Leukemia, Myeloid, Acute/genetics , Nuclear Proteins/physiology , Wnt Signaling Pathway/physiology , Zebrafish/embryology , Animals , Axin Protein/analysis , Hematopoietic Stem Cells/physiology , Leukemia, Myeloid, Acute/etiology , Mutation , Nuclear Proteins/genetics , Nucleophosmin
2.
Expert Rev Anticancer Ther ; 9(9): 1283-94, 2009 Sep.
Article En | MEDLINE | ID: mdl-19761432

Nucleophosmin (NPM) is a nucleolar phosphoprotein implicated in the regulation of multiple cellular functions, which possesses both oncogenic and tumor-suppressor properties. Mutations of the NPM1 gene leading to the expression of a cytoplasmic mutant protein, NPMc+, are the most frequent genetic abnormalities found in acute myeloid leukemias. Acute myeloid leukemias with mutated NPM1 have distinct characteristics, including a significant association with a normal karyotype, involvement of different hematopoietic lineages, a specific gene-expression profile and clinically, a better response to induction therapy and a favorable prognosis. NPMc+ maintains the capacity of wild-type NPM to interact with a variety of cellular proteins, and impairs their activity by delocalizing them to the cytoplasm. In this review we summarize recent discoveries concerning NPM function, and discuss their possible impact on the pathogenesis of acute myeloid leukemias with mutated NPM1.


Gene Expression Regulation, Leukemic , Leukemia, Myeloid, Acute/genetics , Nuclear Proteins/genetics , Animals , Cytoplasm/metabolism , Humans , Leukemia, Myeloid, Acute/pathology , Mutation , Nucleophosmin , Prognosis , Translocation, Genetic
3.
PLoS One ; 4(1): e4273, 2009.
Article En | MEDLINE | ID: mdl-19169355

PRDM genes are a family of transcriptional regulators that modulate cellular processes such as differentiation, cell growth and apoptosis. Some family members are involved in tissue or organ maturation, and are differentially expressed in specific phases of embryonic development. PRDM5 is a recently identified family member that functions as a transcriptional repressor and behaves as a putative tumor suppressor in different types of cancer. Using gene expression profiling, we found that transcriptional targets of PRDM5 in human U2OS cells include critical genes involved in developmental processes, and specifically in regulating wnt signaling. We therefore assessed PRDM5 function in vivo by performing loss-of-function and gain-of-function experiments in zebrafish embryos. Depletion of prdm5 resulted in impairment of morphogenetic movements during gastrulation and increased the occurrence of the masterblind phenotype in axin+/- embryos, characterized by the loss of eyes and telencephalon. Overexpression of PRDM5 mRNA had opposite effects on the development of anterior neural structures, and resulted in embryos with a shorter body axis due to posterior truncation, a bigger head and abnormal somites. In situ hybridization experiments aimed at analyzing the integrity of wnt pathways during gastrulation at the level of the prechordal plate revealed inhibition of non canonical PCP wnt signaling in embryos overexpressing PRDM5, and over-activation of wnt/beta-catenin signaling in embryos lacking Prdm5. Our data demonstrate that PRDM5 regulates the expression of components of both canonical and non canonical wnt pathways and negatively modulates wnt signaling in vivo.


DNA-Binding Proteins/metabolism , Gene Expression Regulation , Transcription Factors/metabolism , Tumor Suppressor Proteins/physiology , Wnt Proteins/metabolism , Zebrafish Proteins/physiology , Animals , Cell Line, Tumor , Gene Expression Profiling , Genes, Tumor Suppressor , Humans , In Situ Hybridization , Neurons/metabolism , Oligonucleotide Array Sequence Analysis , Phenotype , RNA, Messenger/metabolism , Signal Transduction , Tumor Suppressor Proteins/genetics , Zebrafish , Zebrafish Proteins/genetics
4.
BMC Evol Biol ; 7: 187, 2007 Oct 04.
Article En | MEDLINE | ID: mdl-17916234

BACKGROUND: Progressive diversification of paralogs after gene expansion is essential to increase their functional specialization. However, mode and tempo of this divergence remain mostly unclear. Here we report the comparative analysis of PRDM genes, a family of putative transcriptional regulators involved in human tumorigenesis. RESULTS: Our analysis assessed that the PRDM genes originated in metazoans, expanded in vertebrates and further duplicated in primates. We experimentally showed that fast-evolving paralogs are poorly expressed, and that the most recent duplicates, such as primate-specific PRDM7, acquire tissue-specificity. PRDM7 underwent major structural rearrangements that decreased the number of encoded Zn-Fingers and modified gene splicing. Through internal duplication and activation of a non-canonical splice site (GC-AG), PRDM7 can acquire a novel intron. We also detected an alternative isoform that can retain the intron in the mature transcript and that is predominantly expressed in human melanocytes. CONCLUSION: Our findings show that (a) molecular evolution of paralogs correlates with their expression pattern; (b) gene diversification is obtained through massive genomic rearrangements; and (c) splicing modification contributes to the functional specialization of novel genes.


Gene Rearrangement , Multigene Family , Repressor Proteins/genetics , Transcription Factors/genetics , Vertebrates/genetics , Amino Acid Sequence , Animals , DNA Primers , Evolution, Molecular , Gene Duplication , Gene Expression Regulation , Humans , Phylogeny , Reverse Transcriptase Polymerase Chain Reaction , Sequence Alignment , Species Specificity
5.
Blood ; 106(3): 899-902, 2005 Aug 01.
Article En | MEDLINE | ID: mdl-15831697

Approximately one third of acute myeloid leukemias (AMLs) are characterized by aberrant cytoplasmic localization of nucleophosmin (NPMc+ AML), consequent to mutations in the NPM putative nucleolar localization signal. These events are mutually exclusive with the major AML-associated chromosomal rearrangements, and are frequently associated with normal karyotype, FLT3 mutations, and multilineage involvement. We report the gene expression profiles of 78 de novo AMLs (72 with normal karyotype; 6 without major chromosomal abnormalities) that were characterized for the subcellular localization and mutation status of NPM. Unsupervised clustering clearly separated NPMc+ from NPMc- AMLs, regardless of the presence of FLT3 mutations or non-major chromosomal rearrangements, supporting the concept that NPMc+ AML represents a distinct entity. The molecular signature of NPMc+ AML includes up-regulation of several genes putatively involved in the maintenance of a stem-cell phenotype, suggesting that NPMc+ AML may derive from a multipotent hematopoietic progenitor.


Cytoplasm/chemistry , Leukemia, Myeloid/genetics , Leukemia, Myeloid/pathology , Nuclear Proteins/analysis , Up-Regulation/genetics , Acute Disease , Cell Lineage , DNA Mutational Analysis , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Hematopoietic Stem Cells , Leukemia, Myeloid/classification , Neoplasm Proteins/analysis , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Nucleophosmin , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , fms-Like Tyrosine Kinase 3
6.
Oncogene ; 24(20): 3358-68, 2005 May 05.
Article En | MEDLINE | ID: mdl-15735696

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block of differentiation at the promyelocytic stage. APL patients respond to pharmacological concentrations of all-trans retinoic acid (RA) and disease remission correlates with terminal differentiation of leukemic blasts. The PML/RAR oncogenic transcription factor is responsible for both the pathogenesis of APL and for its sensitivity to RA. In order to identify physiological targets of RA therapy, we analysed gene expression profiles of RA-treated APL blasts and found 1056 common target genes. Comparing these results to those obtained in RA-treated U937 cell lines revealed that transcriptional response to RA is largely dependent on the expression of PML/RAR. Several genes involved in the control of differentiation and stem cell renewal are early targets of RA regulation, and may be important effectors of RA response. Modulation of chromatin modifying genes was also observed, suggesting that specific structural changes in local chromatin domains may be required to promote RA-mediated differentiation. Computational analysis of upstream genomic regions in RA target genes revealed nonrandom distribution of transcription factor binding sites, indicating that specific transcriptional regulatory complexes may be involved in determining RA response.


Gene Expression Regulation, Neoplastic , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/genetics , Tretinoin/pharmacology , Binding Sites , Cell Line, Tumor , Chromatin/metabolism , Cluster Analysis , Exons , Humans , Leukemia, Promyelocytic, Acute/metabolism , Oligonucleotide Array Sequence Analysis , Promoter Regions, Genetic , Protein Structure, Tertiary , RNA/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/metabolism , Transcription, Genetic , Tretinoin/metabolism , Tumor Cells, Cultured , U937 Cells
7.
N Engl J Med ; 352(3): 254-66, 2005 Jan 20.
Article En | MEDLINE | ID: mdl-15659725

BACKGROUND: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. METHODS: We used immunohistochemical methods to study the subcellular localization of NPM in bone marrow-biopsy specimens from 591 patients with primary acute myelogenous leukemia (AML). We then correlated the presence of cytoplasmic NPM with clinical and biologic features of the disease. RESULTS: Cytoplasmic NPM was detected in 208 (35.2 percent) of the 591 specimens from patients with primary AML but not in 135 secondary AML specimens or in 980 hematopoietic or extrahematopoietic neoplasms other than AML. It was associated with a wide spectrum of morphologic subtypes of the disease, a normal karyotype, and responsiveness to induction chemotherapy, but not with recurrent genetic abnormalities. There was a high frequency of FLT3 internal tandem duplications and absence of CD34 and CD133 in AML specimens with a normal karyotype and cytoplasmic dislocation of NPM, but not in those in which the protein was restricted to the nucleus. AML specimens with cytoplasmic NPM carried mutations of the NPM gene that were predicted to alter the protein at its C-terminal; this mutant gene caused cytoplasmic localization of NPM in transfected cells. CONCLUSIONS: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.


Bone Marrow/pathology , Cytoplasm/chemistry , Leukemia, Myeloid, Acute/genetics , Mutation , Nuclear Proteins/genetics , Adolescent , Adult , Antibodies, Monoclonal , Antineoplastic Agents/therapeutic use , Base Sequence , Cell Nucleolus , DNA Mutational Analysis , Humans , Karyotyping , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/pathology , Middle Aged , Nuclear Proteins/analysis , Nuclear Proteins/immunology , Nucleophosmin , Remission Induction , Transfection , Translocation, Genetic
8.
Bioinformatics ; 20(18): 3326-35, 2004 Dec 12.
Article En | MEDLINE | ID: mdl-15247102

MOTIVATION: High-throughput technologies create the necessity to mine large amounts of gene annotations from diverse databanks, and to integrate the resulting data. Most databanks can be interrogated only via Web, for a single gene at a time, and query results are generally available only in the HTML format. Although some databanks provide batch retrieval of data via FTP, this requires expertise and resources for locally reimplementing the databank. RESULTS: We developed MyWEST, a tool aimed at researchers without extensive informatics skills or resources, which exploits user-defined templates to easily mine selected annotations from different Web-interfaced databanks, and aggregates and structures results in an automatically updated database. Using microarray results from a model system of retinoic acid-induced differentiation, MyWEST effectively gathered relevant annotations from various biomolecular databanks, highlighted significant biological characteristics and supported a global approach to the understanding of complex cellular mechanisms. AVAILABILITY: MyWEST is freely available for non-profit use at http://www.medinfopoli.polimi.it/MyWEST/


Database Management Systems , Databases, Genetic , Gene Expression Profiling/methods , Information Storage and Retrieval/methods , Internet , Software , User-Computer Interface , Algorithms , Artificial Intelligence , Documentation/methods , Information Dissemination/methods , Natural Language Processing
9.
J Clin Invest ; 112(11): 1751-61, 2003 Dec.
Article En | MEDLINE | ID: mdl-14660751

Acute myelogenous leukemias (AMLs) are genetically heterogeneous and characterized by chromosomal rearrangements that produce fusion proteins with aberrant transcriptional regulatory activities. Expression of AML fusion proteins in transgenic mice increases the risk of myeloid leukemias, suggesting that they induce a preleukemic state. The underlying molecular and biological mechanisms are, however, unknown. To address this issue, we performed a systematic analysis of fusion protein transcriptional targets. We expressed AML1/ETO, PML/RAR, and PLZF/RAR in U937 hemopoietic precursor cells and measured global gene expression using oligonucleotide chips. We identified 1,555 genes regulated concordantly by at least two fusion proteins that were further validated in patient samples and finally classified according to available functional information. Strikingly, we found that AML fusion proteins induce genes involved in the maintenance of the stem cell phenotype and repress DNA repair genes, mainly of the base excision repair pathway. Functional studies confirmed that ectopic expression of fusion proteins constitutively activates pathways leading to increased stem cell renewal (e.g., the Jagged1/Notch pathway) and provokes accumulation of DNA damage. We propose that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins.


DNA Repair , Gene Expression Regulation , Oncogene Proteins, Fusion/physiology , Stem Cells/physiology , Transcription Factors/physiology , Calcium-Binding Proteins , Cell Differentiation , Core Binding Factor Alpha 2 Subunit , Humans , Intercellular Signaling Peptides and Proteins , Jagged-1 Protein , Membrane Proteins , Mutation , Neoplasm Proteins/physiology , Oligonucleotide Array Sequence Analysis , Phenotype , Proteins/physiology , RUNX1 Translocation Partner 1 Protein , Serrate-Jagged Proteins , Signal Transduction , Tretinoin/pharmacology , U937 Cells
...